More search options
Basket icon
No items
Basket icon

Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. E9
Subject category: Entrepreneurship
Authors: William C Lazier (Stanford Law School, Stanford University); John W Glynn (Stanford Graduate School of Business, Stanford University); Kevin Taweel (Stanford Graduate School of Business, Stanford University)
Published by: Stanford Business School
Originally published in: 1993
Version: November 1993
Length: 25 pages
Data source: Field research
Topics: Entrepreneurship; Initial Public Offering (IPO)
Share a link: https://casecent.re/p/6005
| No reviews for this item
This product has not been used yet
View our pricing guide or login to see prices.

Abstract

Case involves an early stage biotechnology company raising its fourth round of money in a very capital intensive field. Should the company do a late stage private equity financing and try to meet its product development goals or take the risk of filing an initial public offering before the key product development and regulatory milestones have been met?
Location:
Northern California, USA
Industry:
Bio-technology
Other setting(s):
1993
Teaching note
-
Reference no. E9T
Subject category: Entrepreneurship
Authors: William C Lazier (Stanford Law School, Stanford University); John W Glynn (Stanford Graduate School of Business, Stanford University); Kevin Taweel (Stanford Graduate School of Business, Stanford University)
Published by: Stanford Business School
Originally published in: 1993
Version: December 1993
Length: 9 pages
Data source: Field research
View full details

About

Abstract

Case involves an early stage biotechnology company raising its fourth round of money in a very capital intensive field. Should the company do a late stage private equity financing and try to meet its product development goals or take the risk of filing an initial public offering before the key product development and regulatory milestones have been met?

Settings

Location:
Northern California, USA
Industry:
Bio-technology
Other setting(s):
1993

Related

Teaching note
-
Reference no. E9T
Subject category: Entrepreneurship
Authors: William C Lazier (Stanford Law School, Stanford University); John W Glynn (Stanford Graduate School of Business, Stanford University); Kevin Taweel (Stanford Graduate School of Business, Stanford University)
Published by: Stanford Business School
Originally published in: 1993
Version: December 1993
Length: 9 pages
Data source: Field research
View full details